These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25999373)

  • 1. Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?
    Tesar V
    Nephrol Dial Transplant; 2015 Jul; 30(7):1088-90. PubMed ID: 25999373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
    Kronbichler A; Jayne DR
    Nephrol Dial Transplant; 2015 Jul; 30(7):1075-81. PubMed ID: 25999374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
    Specks U
    Nephrol Dial Transplant; 2015 Jul; 30(7):1083-7. PubMed ID: 25999375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kallenberg CG; Hauser T
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.
    Turner-Stokes T; Sandhu E; Pepper RJ; Stolagiewicz NE; Ashley C; Dinneen D; Howie AJ; Salama AD; Burns A; Little MA
    Rheumatology (Oxford); 2014 Aug; 53(8):1395-403. PubMed ID: 24609057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
    Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
    Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ANCA-associated renal vasculitis - an update.
    Tesar V; Hruskova Z
    Contrib Nephrol; 2013; 181():216-28. PubMed ID: 23689583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in experts' opinions regarding risks and treatment choices in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
    Cozmuta R; Merkel PA; Fraenkel L
    J Clin Rheumatol; 2013 Dec; 19(8):426-31. PubMed ID: 24263144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?
    Tarzi R; Pusey C
    Nat Rev Nephrol; 2013 Nov; 9(11):628-9. PubMed ID: 24080801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ANCA-associated vasculitis].
    Holle JU
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
    McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.